Kornimate/medical-research-clean huggingface dataset:
bone marrow transplant from related donor for patients with high risk hemoglobinopathies

Conditions: Sickle Cell Anemia; Hemoglobinopathy; Thalassemia

Summary: the major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. participation in this project will be for two years.

to do the bone marrow transplant, we must first kill the cells in the bone marrow that make the abnormal red blood cells that are found in patients with severe thalassemia or sickle cell disease. we will do this by using three drugs: busulfan, cyclophosphamide, and campath-1h. campath-ih is an investigational drug. campath-1h is used to prevent participants from rejecting or refusing to let the donor blood cells grow in the body. after the drug treatment, participants will be given bone marrow from a brother or sister who has healthy bone marrow that matches.

Eligibility criteria:
inclusion: * patients with homozygous b0/+ thalassemia or severe variants of b0/+ thalassemia with an hla genotypically identical donor. * patients with an hla genotype identical donor and hemoglobin ss, hemoglobin sc, or hemoglobin sb 0/+ and at least one of the following: previous central nervous system vaso-occlusive episode with or without residual neurologic findings; frequent painful vaso-occlusive episodes which significantly interfere with normal life activities and which necessitate chronic transfusion therapy; recurrent scd chest syndrome events which necessitate chronic transfusion therapy. * severe anemia which prevents acceptable quality of life and necessitates chronic transfusion therapy. * the patient must have an hla genotype identical donor. * between the ages of birth and 65 years. * women of childbearing potential must have a negative pregnancy test. exclusion: * biopsy proven chronic active hepatitis or fibrosis with portal bridging. * scd chronic lung disease \>/= stage 3. * severe renal dysfunction defined as creatinine clearance \<40 ml/min/1.73 m2 * severe cardiac dysfunction defined as shortening fraction \<25%. * hiv infection. * severe but unspecified chronic toxicity serious enough to detrimentally affect the patient's capacity to tolerate bone marrow transplant (bmt). * inadequate intellectual capacity to understand the nature and risk inherent in the bmt process and give informed consent (in the case of minors, this criteria must be fulfilled by the legal guardian). * pregnant, lactating or unwilling to use appropriate birth control.
follow-up during the peripubertal period of preterm children included in the protocol entitled "epipod".

Conditions: Preterm Children

Summary: prematurity is associated with an increased risk of developing cardiovascular and metabolic disturbances in adulthood. it has been demonstrated that the body composition of children born prematurely is different from that of children born under term with a deficit in fat free mass. it can thus be wondered if this excessive adiposity does or does not predict the risk of insulin resistance in adulthood. children born prematurely, with a body composition measurement performed at discharge from neonatal hospitalization as part of the epipod protocol, and now aged between 8 and 14 years, will be included in the infantpod protocol. analysis of body composition, insulin resistance, renal function, pulse wave velocity, eating behaviour and of physical activity will be performed.


Eligibility criteria:
inclusion criteria: * children hospitalised at the nantes university hospital in the neonatal period * with a body composition measurement performed at discharge from neonatal hospitalization as part of the epipod protocol * born prematurely (under 35 weeks of amenorrhea) * included in the lift cohort with follow-up up to 7 years * aged between 8 and 14 years at inclusion exclusion criteria: * children with an isolated metabolic disease: insulin-dependent diabetes; endocrine disease (cushing's, hypothyroidism) * age of 15 years or more * with a chromosomal anomaly * with contraindicating measurement of the bop-pod: ventilatory support, continuous parenteral feeding, elimination stoma * refusal of either parent or child
study of febrile syndromes after tick bite

Conditions: Febrile Syndrome

Summary: febrile syndromes after tick bites can be caused by different microorganisms: bacteria (b. miyamotoi, a. phagocytophilum, r. helvetica...), parasites (babesia spp) and viruses (tbe virus). the clinical picture is not specific but complications may appear depending on the microorganism identified (thrombosis with n. mikurensis, meningoencephalitis with b. miyamotoi and the tbe virus). thus, in order to provide appropriate treatment and monitoring, the infection should be documented.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years old) * subject whose sample was sent to the bacteriology laboratory for research on anaplasma phagocytophilum between 2009 and august 2020 exclusion criteria: * subject having expressed his opposition to his medical data and biological resources not being reused for scientific research. * subject under guardianship or guardianship * subject under safeguard of justice

Keywords: febrile syndrome tick bite anaplasma phagocytophilum
effects of aquatic therapy versus neuro-dynamic technique for the treatment of carpal tunnel syndrome patient

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome (cts) is a common neurological disorder due to entrapment of median nerve which runs from the forearm into the hand through a tunnel, compressed or pinched due to anatomical factors, such as a narrow carpal tunnel. widespread condition that affects 3-6% of the general population worldwide. carpal tunnel syndrome (cts) a prevalent and debilitating condition leading to disability despite optimal interventions to rehabilitation that aimed to reducing pain and improving neural function status in carpal tunnel syndrome patients .

this study investigates the additional benefits of aquatic therapy and neuro-dynamic technique in carpal tunnel syndrome patients .the researcher employs a randomized controlled trial methodology. participants are divided into two groups: one receiving aquatic therapy, and the other receiving neuro-dynamic technique. outcomes are assessed over an 8-week period, focusing on pain levels and neural function restoration and grip strength. the significance of this study lies in its potential to enhance current treatment protocols, offering a more effective, intervention to alleviate symptoms and improve the quality of life, neural restoration for those suffering carpal tunnel syndrome (cts).

Eligibility criteria:
inclusion criteria: * diagnosed with mild-to-moderate carpal tunnel syndrome by neuromuscular physician * participants who presented with unilateral cts with symptoms reported up to 3 months * male and female * aged 18 years or older exclusion criteria: * patients with non-specified stage of cts,median nerve entrapment in tos, cervical radiculpathy * participants presents with co-morbidities,hx of cts (e.g., pregnancy, diabetes, trauma, congenital disorders, obesity, post-surgical release, and hypothyroidism) * cardiovascular disease, thenar muscle atropy"
radiation therapy plus durvalumab for tumor-stage cutaneous t-cell lymphoma

Conditions: Cutaneous T Cell Lymphoma

Summary: this is a single arm, single stage pilot study of radiation therapy plus durvalumab for tumor-stage cutaneous t-cell lymphoma (ctcl).


Eligibility criteria:
inclusion criteria: * voluntarily provide written irb-approved consent * age ≥ 18 years * histologically proven ctcl * stage iib-iv ctcl with ≥2 cutaneous tumors assessable for response * at least one cutaneous tumor amenable to radiation therapy. must have at least 1 tumor assessable for response that will not undergo radiation. * adequate organ function * prior treatment is allowed if at least 4 weeks have elapsed since last chemotherapy and/or radiation and the subject has recovered from all treatment related toxicity exclusion criteria: * prior allogeneic stem cell transplant. * prior treatment with a pd-1/pd-l1 inhibitor * active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment. * current or prior use of immunosuppressive medication within 14 days prior to first dose of durvalumab. * known human immunodeficiency virus (hiv), hepatitis c virus (hcv) or active hepatitis b virus (hbv) infection. * history of hypersensitivity to durvalumab or any excipient * receipt of live attenuated vaccination within 30 days prior the first dose of durvalumab. * female subjects who are pregnant, breast-feeding or female patients of reproductive potential who are not employing an effective method of birth control * male subjects who are not employing an effective method of birth control * uncontrolled current medical illness, including, but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris,unstable cardiac arrhythmia and/or psychiatric illness or other condition that in the opinion of the investigator would limit compliance with study requirements.
developing asthma interventions using community based research

Conditions: Asthma

Summary: the purpose of this study is to identify community resources and challenges in improving the health of community members with asthma. the primary goal of this project is to use community-based participatory research methodology to develop interventions aimed at improving asthma management in high-risk african american asthmatics. this "ground-up" longterm approach has never been tested before in asthmatics. the primary goal of this study will be accomplished with four specific aims: aim 1. conduct focus groups to identify barriers to asthma management in the target population. aim 2. use a community advisory board (cab) consisting of participants selected from the various focus groups to gather information about solutions for the above barriers. aim 3. use the information from the cab to develop an intervention to improve asthma self management behaviors in the target population. aim 4. refine the developed intervention based on feedback from focus groups conducted in aim 1.

volunteer will be asked to respond to several questions that address their perceptions about asthma. volunteers will also be asked to discuss their beliefs about asthma. everyone in the group will be given an opportunity to answer questions. volunteers can decide that they no longer want to participate in the group discussion at any time. the discussion will last from 1.5 - 2 hours. the focus group discussion will have a maximum of 10 people. we will be audio and video taping the discussion so that we do not miss any information that volunteers share with us. the audio and video tapes will not be shared with anyone outside our staff. volunteer participation in this study is voluntary and there will be no negative consequences if volunteers decide not to participate. volunteers are also free to withdraw from this study at any time. withdrawal or refusal to participate will not affect health care services or other rights.

Eligibility criteria:
inclusion criteria: * self-identified african-american, 18 yrs. or older, resident of davidson county, tennessee at least 1 year. exclusion criteria: * under 18 yrs. of age * non-african american * non-english speaking * do not reside in davidson county, tennessee

Keywords: asthma focus group community based participatory research
guided internet-delivered cognitive-behavioral therapy for former chronic pain patients

Conditions: Chronic Pain

Summary: the aim of the present study was to investigate if guided internet-delivered cognitive-behavioral therapy (cbt) would help chronic pain patients who had previously undergone a multidisciplinary treatment but still have residual problems.

the present study investigates internet-delivered cbt as a tertiary intervention. this is motivated by the fact that many pain patients relapse after rehabilitation and some may be in need of additional treatment. the persons who fulfills the inclusion criteria undergoes a structured telephone interview. the study is a experimental design with a treatment and an active control group measured before and after a treatment period. the control group were invited to participate in a moderated online discussion forum. follow up data was collected six months after the treatment.

Eligibility criteria:
inclusion criteria: * to have been medically investigated (within one year) * completed the multidisciplinary rehabilitation program * have residual symptoms after the rehabilitation treatment (defined as functional impairment caused by their pain) * have internet access exclusion criteria: * planned surgery * ongoing medical investigation that could impede participation in the study * suffering from acute physical or psychological conditions * people confined to wheelchairs * people not fluent with the swedish language

Keywords: chronic pain internet delivered cbt tertiary intervention mindfulness applied relaxation guided self help
amyotrophic lateral sclerosis registry rhineland-palatinate

Conditions: Amyotrophic Lateral Sclerosis

Summary: there is a lack of prospective and population-based epidemiological data on amyotrophic lateral sclerosis in germany so far. the purpose of this registry is to investigate the incidence, course and phenotypic variety of als in rhineland-palatinate, a south-west german state of about 4 million inhabitants.


Eligibility criteria:
inclusion criteria: * diagnosis of amyotrophic lateral sclerosis according to revised el escorial criteria * minimum of 18 years * minimum of 6 months of residency in rhinelnad-palatinate exclusion criteria: * patients below 18 years * als patients outside rhineland-palatinate

Keywords: incidence phenotype mortality
smc021a - absorption, efficacy and tolerance in patients with osteoarthritis. a placebo-controlled 14-days study

Conditions: Osteoarthritis

Summary: the purpose of this study is to expose patients with oa to calcitonin and to determine plasma calcitonin levels after administration of 0.6 mg and 0.8 mg oral calcitonin. also the purpose is to assess the effect of different doses of oral calcitonin (0.6 mg and 0.8 mg oral) compared to placebo on serum ctx-i and ctx-ii. finally to assess the tolerance profile of different doses/formulations of oral calcitonin compared to placebo.


Eligibility criteria:
inclusion criteria: * medical history and symptoms of knee osteoarthritis exclusion criteria: * any other disease or medication affecting the bone or cartilage. * any clinical signs or laboratory evidence diseases, which in the investigator's opinion would preclude the participant from adhering to the protocol or completing the trial.

Keywords: osteoarthritis, oral salmon calcitonin, tolerability, biomarkers
time of cannulation during primary ercp with short guide wire rapid exchange or with long guide wire

Conditions: Pancreatitis

Summary: the aim of this study is to compare the cannulation time during primary wire guided ercp (endoscopic retrograde cholangio-pancreatography) according to two different length of guide wire: long wire or short wire rapid exchange, artery by a prospective randomized trial.

in primary endoscopic retrograde cholangio-pancreatography (ercp) cannulation is wire guided. up to now there is no doubt about the efficacy of such a procedure. the use of long wire requires the help of another person behind primary operator. the use of short wire rapid exchange allows the primary operator to perform all the steps by himself. time of cannulation is known to be directly associated to post ercp pancreatitis. aim of the study is to assess which length of guide wire allows the shorter cannulation time during primary ercp. post ercp pancreatitis onset will be assessed for all patients

Eligibility criteria:
inclusion criteria: * indication to primary ercp * asa (american society of anesthesiologists) 1, 2, 3 exclusion criteria: * pancreas neoplasia * pancreatitis * ampulloma * duodenum stenosis * under mucous membrane haematoma

Keywords: guide wire cannulation ercp time of cannulation rapid exchange guide wire guide wire
a time to cardiovascular event analysis comparing tocilizumab to other biologics in patients with rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: this retrospective cohort study will analyze data from multiple large u.s. health insurance claims databases to compare use of tocilizumab to other biologic disease-modifying anti-rheumatic drugs (dmards) in real world patients with ra. using the date of dispensing as the index date, the analysis will compute the time to first event for several cardiovascular outcomes.


Eligibility criteria:
inclusion criteria: * at least 1 inpatient or 2 outpatient diagnoses of ra * continuous medical/pharmacy coverage and full claims data available * at least 6 months of insurance plan enrollment prior to index date exclusion criteria: * nursing home residents * human immunodeficiency virus (hiv) * malignancy * receipt of chemotherapy * end-stage renal disease, dialysis, or transplant * use of rituximab * recent cardiovascular event (includes mi, stroke, acs, or hf) within 90 days prior to index date
biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate

Conditions: Lung Cancer

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is studying biomarkers in blood samples from patients with refractory non-small cell lung cancer previously treated with sorafenib tosylate.

objectives: * to determine the mutation rates of braf, kras, and egfr in patients with non-small cell lung cancer treated with sorafenib tosylate on protocol ecog-2501. * to determine the association between braf, kras, or egfr mutation status and clinical benefits in patients treated with this regimen. outline: this is a multicenter study. dna is isolated from archived plasma samples and analyzed for braf, kras, and egfr mutations.

Eligibility criteria:
disease characteristics: * diagnosis of refractory non-small cell lung cancer * received sorafenib tosylate on protocol ecog-e2501 * available blood specimens patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: recurrent non-small cell lung cancer stage iiib non-small cell lung cancer stage iv non-small cell lung cancer
efficacy and safety of cd5789 (trifarotene) 50μg/g cream versus vehicle cream in acne vulgaris

Conditions: Acne Vulgaris

Summary: assessment of the efficacy and safety of cd5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

clinical trial for each subject is approximately 14 weeks and are randomized to one of the two treatments for 12 weeks. subjects must be 9 years of age and older with acne vulgaris.

Eligibility criteria:
inclusion criteria: * the subject is a male or female, 9 years of age or older, at screening visit. * the subject has moderate acne at screening and baseline. * the subject is a female of non childbearing potential * the subject is a female of childbearing potential with a negative pregnancy test and who is strictly abstinent or who agrees to use an effective and approved contraceptive method for the duration of the study and at least 1 month after the last study drug application. exclusion criteria: * the subject has severe forms of acne (e.g., acne conglobate, acne fulminant) or secondary acne form (e.g.,chloracne, drug-induced acne, etc.). * the subject has any uncontrolled or serious disease or any medical or surgical condition that may either interfere with the interpretation of the trial results and/or put the subject at significant risk (according to the investigator's judgment) if the subject takes part to the trial. * the subject has been exposed to excessive ultraviolet (uv) radiation within one month prior to the baseline visit or the subject is planning intense uv exposure during the study (i.e., occupational exposure to the sun, sunbathing, tanning salon use, phototherapy, etc.) * the subject is unwilling to refrain from use of prohibited medication during the clinical trial

Keywords: efficacy safety acne vulgaris
hpv integration and tumorigenesis of uterine cervical adenocarcinoma

Conditions: Cervical Adenocarcinoma; Human Papillomavirus; Genome-wide Association Study; Whole Exome Sequencing; Transcriptome; Metabolome; Tumorigenesis; Prognosis

Summary: this study aims to analyze the multi-omics results between uterine cervical adenocarcinoma patients with and without human papillomavirus (hpv) infections. the multi-omics profiles include genome wide association study (gwas), whole exome sequencing, analysis of transcriptomics and metabolomics. the hpv integration status is interpreted by gwas. a comprehensive multi-omics will reveal the role of hpv integration in the molecular mechanism of tumorigenesis and prognosis of uterine cervical adenocarcinoma.


Eligibility criteria:
inclusion criteria: * confirmed primary adenocarcinoma of the uterine cervix * signed an approved informed consents * feasible for biopsy exclusion criteria: * not meeting all of the inclusion criteria
elitek (rasburicase) immuno-monitoring study

Conditions: Tumor Lysis Syndrome

Summary: primary objective: to determine the incidence, titer and type of anti-rasburicase antibodies in the context of hypersensitivity reaction(s) or the loss of uricolytic activity occurring in patients with relapsed leukemia/lymphoma who have been re-treated with rasburicase and have experienced a hypersensitivity reaction or loss of uricolytic activity.


Eligibility criteria:
inclusion criteria: 1. previous history of rasburicase exposure and history of administration of a repeat (2nd) series of rasburicase injections (in the context of supportive care for relapsing leukemia/lymphoma) and subsequent development of either a hypersensitivity reaction (hsr) or loss of uricolytic activity (defined as failure to achieve uric acid level of \< or = 7.5 mg/dl measured 48 hours after the first rasburicase injection). 1. a severe hypersensitivity reaction (nci grade 3, 4 or 5) is defined as: allergic reaction; allergy; anaphylactic shock; bronchospasm; bullous skin eruption; dermatitis - exfoliative; drug hypersensitivity; dyspnea; hypotension; hypoxia; rash; rash - erythematous; rash - maculopapular, urticaria; pyrexia/fever; edema; chest discomfort; hypersensitivity (nos); pharynx discomfort; hoarseness; pharyngeal erythema; pruritus; erythema; localized exfoliation; rash - papular; swelling ¿ face/facial; toxic skin eruption; hot flush; flushing; rash - macular; rash - pruritic; pruritus - allergic. 2. loss of uricolytic activity can be defined as: * uric acid levels \> 7.5 mg/dl measured 48 hours after the first rasburicase injection¿, which is a time point coincident with administration of the third dose of rasburicase (within that second course of treatment with this agent). 2. patients should have received at least 2 doses of rasburicase during the repeat (2nd) administration in the event of loss or uricolytic activity. at least 1 dose of rasburicase should be administered during the repeat (2nd) administration for diagnosis of hsr. exclusion criteria: 1. concomitant treatment with human iv immunoglobulin (ivig) 2. concomitant treatment with tnf-alpha antagonists/inhibitors, i.e. adalimumab, infliximab, and etanercept 3. concomitant treatment with interferon-alpha (ifn-alpha) 4. unwillingness or inability to comply with the requirements of the protocol. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.